Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117.

Journal article

Zacharopoulou P. et al, (2022), Curr Opin HIV AIDS, 17, 352 - 358

An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect.

Journal article

Tipoe T. et al, (2022), Curr Opin HIV AIDS, 17, 162 - 170

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Journal article

Ogbe A. et al, (2022), JCI Insight, 7

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Journal article

Tomic A. et al, (2022), Nat Commun, 13

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Journal article

Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Journal article

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Human MAIT cells respond to and suppress HIV-1.

Journal article

Phetsouphanh C. et al, (2021), Elife, 10

Immunotherapeutic approaches to HIV cure and remission

Journal article

Lee MJ. et al, (2021), Current Opinion in Infectious Diseases, Publish Ahead of Print

Load More